공정 개발 및 최적화
기술 범위, 품질 수준, 배치 문서, 납품 요건은 프로젝트 단계에 맞춰 구성할 수 있습니다.
생물학적 연구 및 산업적 용도로 설계되었으며, 개인의 임상 또는 의료 목적으로는 사용할 수 없습니다.
초기 기술 검토부터 스케일업 및 안정적 공급까지 아우르는 통합 펩타이드 CDMO 지원입니다.
핵심 역량
파일럿 및 GMP 생산 조율
기술 범위, 품질 수준, 배치 문서, 납품 요건은 프로젝트 단계에 맞춰 구성할 수 있습니다.
불순물 전략 및 배치 출하 지원
기술 범위, 품질 수준, 배치 문서, 납품 요건은 프로젝트 단계에 맞춰 구성할 수 있습니다.
제약 파트너를 위한 맞춤 프로젝트 관리
기술 범위, 품질 수준, 배치 문서, 납품 요건은 프로젝트 단계에 맞춰 구성할 수 있습니다.
일반 진행 절차
1요구사항 검토
2기술적 타당성
3견적 및 일정
4합성 또는 공정 수행
5QC 문서
6출하 및 후속 지원
| 개발 단계 | 펩타이드 지원 |
|---|---|
| 개념 및 타당성 | 펩타이드 설계 전략, 서열 최적화 및 타당성 평가 |
| 탐색 연구 | 맞춤 펩타이드 합성, 표적 펩타이드 설계 및 기능 스크리닝 지원 |
| 선도물질 최적화 | 펩타이드 변형, 접합 전략 및 구조-기능 최적화 |
| 공정 개발 | 경로 최적화, 공정 견고성 및 불순물 관리 전략 |
| GMP 제조 | GMP 준수 펩타이드 합성, 품질 문서 및 배치 출하 지원 |
기술 노트
Where the cost sits at scale
At milligram scale, cost is dominated by labour and turnaround. At kilogram scale it shifts to raw materials, solvent volume and waste handling. That reversal is why a route optimised for speed at small scale is often the wrong route at large scale: an expensive coupling reagent that saves an afternoon is immaterial in a screening batch and significant in a campaign. Route selection for a commercial process is therefore made against the intended scale, not the current one.
Stepwise synthesis versus fragment condensation
In stepwise synthesis every cycle multiplies into the overall yield, so long sequences lose material rapidly even at high per-step efficiency. Fragment condensation builds and purifies shorter pieces separately and joins them, which allows failures to be removed before the final assembly and improves overall yield for long targets. It adds the problem of joining the fragments cleanly, including control of racemisation at the junction, so the choice is made per sequence.
Purification at scale
Preparative chromatography usually dominates both the cost and the solvent footprint of a peptide process. The levers are loading, gradient design, and how the collected fractions are pooled, all of which trade recovery against purity. Reworking off-specification fractions can recover material but adds cycle time and its own impurity considerations. These decisions are made deliberately during development, since they set the economics of every batch afterwards.
In-process controls
Controls exist to catch a problem while it can still be fixed, not to document it afterwards. In peptide manufacture that typically means monitoring coupling completion before proceeding, checking cleavage and deprotection are complete, and confirming the crude profile before committing material to purification. Where a control sits and what it triggers is part of process design, because a control with no defined action attached to it is only paperwork.
Change control after transfer
Once a process is established, changes to it need to be assessed for their effect on the product rather than applied because they are locally convenient. A different supplier for a protected amino acid, a modified purification gradient or a new column lot can all shift the impurity profile. Controlled change is what keeps material made next year comparable to material made this year, which is the entire basis of a long-term supply arrangement.
제공 항목
- Route assessment covering yield, impurity profile and scalability
- Developed process description at the agreed scale
- Analytical methods matched to the impurities the process produces
- Technology transfer documentation including critical parameters
- Manufactured batches against the agreed specification
주요 적용 분야
Taking a route from laboratory to production — Where a sequence has been made successfully at small scale and the question is whether that route survives scale-up, or whether a different one is needed.
Improving an existing process — Reducing cost, solvent consumption or cycle time on a process already in use, with the impurity profile kept comparable throughout.
Second-source and dual-supply setup — Establishing an alternative manufacturing route for a peptide already supplied elsewhere, including comparability against the incumbent.
Scale-dependent feasibility — Assessing before committing whether a target is realistic at the intended scale and cost, including the case where the answer is that it is not.
자주 묻는 질문
What is the difference between a CDMO and a custom synthesis supplier?
Custom synthesis delivers a quantity of material. A CDMO engagement takes on the process: developing it, transferring it, and manufacturing to it repeatedly under a quality framework. If you need material once, custom synthesis is the right route. If you need the same material reproducibly for years, the process itself is the deliverable.
What do you need to assess a project?
The sequence and any modifications, the intended scale and how it is expected to grow, the required quality level and regulatory pathway, and any existing process and analytical data. Prior data is particularly valuable, including data from batches that failed, since it usually indicates where the difficulty is.
Can you take over a process developed elsewhere?
Yes. Transfer works best with the full package: process description, analytical methods, specifications, and the batch history that shows how the process behaves in practice. Where documentation is incomplete, part of the work is re-establishing what the critical parameters actually are before scaling anything.
How is scale-up risk managed?
By identifying which parameters the process is sensitive to before changing scale, and by scaling in steps rather than in one move. The steps most likely to behave differently are those where mixing, heat transfer or reaction time change materially with vessel size, and those are the ones examined first.
Does the impurity profile change with scale?
Frequently, yes, and that is why analytical work runs alongside scale-up rather than after it. Longer processing times, different mixing and revised purification loading can all shift which impurities appear and in what proportion. Detecting that shift early is what keeps a specification from being written against a process that no longer exists.
How early should a CDMO be involved?
Earlier than is typical. Decisions taken during discovery, such as which unnatural residues or modifications a sequence contains, can determine whether it is manufacturable at scale at all. Reviewing that while the sequence can still be changed is considerably cheaper than discovering it once the sequence is fixed.
관련 펩타이드 제품
단일 펩타이드
단일 펩타이드 제품 전체 카탈로그를 확인하세요. 견적은 문의 기준입니다.
더 보기DSIP (5 mg 바이알)
DSIP (5 mg 바이알): 연구 실험실을 위한 재구성 참고 자료입니다. 희석액 용량과 그에 따른 농도, 주사기 단위 환산, 바이알 및 소모품 계획, 보관 지침을 포함합니다.
더 보기GHK-Cu (50 mg 바이알)
동결건조 형태로 공급되는 GHK-Cu (50 mg 바이알)의 취급 안내입니다. 재구성 용량과 얻어지는 농도, U-100 주사기 단위 환산, 프로토콜별 소모품 수량, 보관 조건을 다룹니다.
더 보기Ipamorelin (5 mg 바이알)
Ipamorelin (5 mg 바이알): 연구 실험실을 위한 재구성 참고 자료입니다. 희석액 용량과 그에 따른 농도, 주사기 단위 환산, 바이알 및 소모품 계획, 보관 지침을 포함합니다.
더 보기